Current Report Filing (8-k)
2013年10月25日 - 5:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 24, 2013
PURE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE |
|
001-14468 |
|
33-0530289 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
1725 Gillespie Way
El Cajon, California 92020
(Address of Principal Executive Offices)
(619) 596-8600
(Registrants telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 2.02 |
RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
On October 24, 2013, PURE
Bioscience, Inc. (the Company) issued a press release announcing financial results for the fiscal year ended July 31, 2013 and related information. A copy of the press release is attached as Exhibit 99.1.
The information in this Item 2.02 is being furnished and shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and
Exchange Commission.
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
The following exhibit is furnished with this report:
|
|
|
Exhibit No. |
|
Exhibit Description |
|
|
99.1 |
|
Press Release issued by the Company on October 24, 2013. |
* Exhibit
99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any
registration statement or other document filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PURE BIOSCIENCE, INC. |
|
|
|
|
Dated: October 24, 2013 |
|
|
|
By: |
|
/s/ Henry R. Lambert |
|
|
|
|
|
|
Henry R. Lambert, |
|
|
|
|
|
|
Chief Executive Officer |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Exhibit Description |
|
|
99.1 |
|
Press Release issued by the Company on October 24, 2013 |
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about PURE Bioscience Inc (PK) (その他OTC): 0 recent articles
その他のPure Bioscience, Inc.ニュース記事